Gene expression data of cancer cell lines treated with inhibitors of G9a and EZH2

Epigenetic modifications modulate gene expression and, when deregulated, contribute to the development and progression of cancer. G9a (EHMT2) and EZH2 are two histone methyltransferases commonly upregulated in several cancer types, leading to the silencing of tumor suppressor genes. We performed high throughput sequencing of a breast cancer cell line (MDA-MB-231), an ovarian cancer cell line (CAOV3) and a melanoma cell line (D14) treated with a G9a inhibitor (UNC0642), EZH2 inhibitor (GSK126) and their combination. Overall design: MDA-MB-231, CAOV3 and D14 cells were treated with Vehicle (DMSO), UNC0642 (5 µM), GSK126 (10 µM) for 8 hours. RNA was then extracted and libraries were prepared using the Illumina Total RNA Stranded (Ribo-zero Gold) kit.

表观遗传修饰（epigenetic modifications）可调控基因表达，当其发生失调时，会促进癌症的发生与进展。G9a（EHMT2）与EZH2是两类在多种癌症中常见上调的组蛋白甲基转移酶（histone methyltransferases），可介导抑癌基因的转录沉默。本研究对经G9a抑制剂UNC0642、EZH2抑制剂GSK126及其联合处理的乳腺癌细胞系MDA-MB-231、卵巢癌细胞系CAOV3以及黑色素瘤细胞系D14开展了高通量测序（high throughput sequencing）。整体实验设计如下：将MDA-MB-231、CAOV3和D14细胞分别以载体对照（二甲基亚砜，DMSO）、UNC0642（5 μM）、GSK126（10 μM）处理8小时。随后提取总RNA，并使用Illumina Total RNA Stranded（Ribo-zero Gold）试剂盒构建测序文库。